Targeting Glucose Metabolism Enzymes in Cancer Treatment: Current and Emerging Strategies
Open accessThe DOI matches its Crossref record; 316 of the 322 references it cites were found in a registry or an index.
Abstract
Reprogramming of glucose metabolism provides sufficient energy and raw materials for the proliferation, metastasis, and immune escape of cancer cells, which is enabled by glucose metabolism-related enzymes that are abundantly expressed in a broad range of cancers. Therefore, targeting glucose metabolism enzymes has emerged as a promising strategy for anticancer drug development. Although several glucose metabolism modulators have been approved for cancer treatment in recent years, some limitations exist, such as a short half-life, poor solubility, and numerous adverse effects. With the rapid development of medicinal chemicals, more advanced and effective glucose metabolism enzyme-targeted anticancer drugs have been developed. Additionally, several studies have found that some natural products can suppress cancer progression by regulating glucose metabolism enzymes. In this review, we summarize the mechanisms underlying the reprogramming of glucose metabolism and present enzymes that could serve as therapeutic targets. In addition, we systematically review the existing drugs targeting glucose metabolism enzymes, including small-molecule modulators and natural products. Finally, the opportunities and challenges for glucose metabolism enzyme-targeted anticancer drugs are also discussed. In conclusion, combining glucose metabolism modulators with conventional anticancer drugs may be a promising cancer treatment strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“While many of these have shown efficacy in pre-clinical models, challenges in achieving selectivity, combined with pathway redundancies and bypass mechanisms may limit their utility as single agents in the clinic [55].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [55]
The cited source says what the claim attributes to it.
In the citing paper
“Similarly, anti-cancer agents that target the multiple steps of glucose metabolism from glucose uptake to lactate production have also been developed (Table 2) [55].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“For most malignant tumors, angiogenesis, a hallmark of cancer, is not only a significant feature but also a drug target [74].”
BackgroundTargeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 4×
“In the 1920s, Otto Warburg first observed that cancer cells tend to metabolize glucose to lactate even in the presence of sufficient oxygen, known as the Warburg effect or aerobic glycolysis (Figure 1B) [2].”
BackgroundInfluentialThe Warburg Effect: How Does it Benefit Cancer Cells?
Liberti, M. V., & Locasale, J. W. (2016) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2015.12.001 · Cited by 5,150 · cited 1×
“Although the energy produced by each glucose molecule during aerobic glycolysis is less than that produced by OXPHOS, aerobic glycolysis can generate a number of ATP molecules comparable to OXPHOS when the amount of glucose is sufficient [16].”
BackgroundMetabolic regulation of gene expression by histone lactylation
Zhang, D., Tang, Z., Huang, H., Zhou, G., Cui, C., Weng, Y., Liu, W., Kim, S., Lee, S., Perez-Neut, M., et al. (2019) · Nature · doi:10.1038/s41586-019-1678-1 · Cited by 4,371 · cited 1×
“Lactate participates in the homeostatic regulation of M1 macrophages [20] and inhibits CD8+ T cells and natural killer cells (NK cells) from producing γ-interferon [21], which in turn maintains an immunosuppressive microenvironment [22,23].”
BackgroundA guide to immunometabolism for immunologists
O'Neill, L. A. J., Kishton, R. J., & Rathmell, J. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.70 · Cited by 3,315
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057 · cited 1×
“Oxidative phosphorylation (OXPHOS) and anaerobic glycolysis are the two major catabolic glucose pathways, in which glycolysis is the common initiation pathway of both [1].”
BackgroundMetabolic reprogramming and cancer progression
Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020) · Science · doi:10.1126/science.aaw5473 · Cited by 2,740 · cited 1×
“Extensive studies have confirmed that metabolic reprogramming of glucose, which plays a vital role in the proliferation, invasion and metastasis of cancer cells, is closely associated with the survival of cancer cells [24,25].”
BackgroundOne-Carbon Metabolism in Health and Disease
Ducker, G. S., & Rabinowitz, J. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.009 · Cited by 2,239 · cited 3×
“For example, glucose-6-phosphate (G-6-P) is a substrate for the pentose phosphate pathway that produces reduced nicotinamide adenine dinucleotide phosphate (NADPH) and ribose-5-phosphate (R-5-P) substrates, and R-5-P is a substrate for nucleic acid synthesis.”
BackgroundYang, A., Kaghad, M., Wang, Y., Gillett, E., Fleming, M. D., Dötsch, V., Andrews, N. C., Caput, D., & McKeon, F. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80275-0 · Cited by 2,085
Inhibitory effect of tumor cell-derived lactic acid on human T cells
Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., et al. (2007) · Blood · doi:10.1182/blood-2006-07-035972 · Cited by 1,946 · cited 1×
“Lactate participates in the homeostatic regulation of M1 macrophages [20] and inhibits CD8+ T cells and natural killer cells (NK cells) from producing γ-interferon [21], which in turn maintains an immunosuppressive microenvironment [22,23].”
BackgroundReductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia
Metallo, C. M., Gameiro, P. A., Bell, E. L., Mattaini, K. R., Yang, J., Hiller, K., Jewell, C. M., Johnson, Z. R., Irvine, D. J., Guarente, L., et al. (2012) · Nature · doi:10.1038/nature10602 · Cited by 1,791
Glucose feeds the TCA cycle via circulating lactate
Hui, S., Ghergurovich, J. M., Morscher, R. J., Jang, C., Teng, X., Lu, W., Esparza, L. A., Reya, T., Zhan, L., Yanxiang Guo, J., et al. (2017) · Nature · doi:10.1038/nature24057 · Cited by 1,721
Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.-C., Valent, A., Minty, A., Chalon, P., Lelias, J.-M., Dumont, X., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80540-1 · Cited by 1,637
Targeting mitochondria for cancer therapy
Fulda, S., Galluzzi, L., & Kroemer, G. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3137 · Cited by 1,629
Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression
Le, A., Cooper, C. R., Gouw, A. M., Dinavahi, R., Maitra, A., Deck, L. M., Royer, R. E., Vander Jagt, D. L., Semenza, G. L., & Dang, C. V. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914433107 · Cited by 1,516
Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses
Ho, P.-C., Bihuniak, J. D., Macintyre, A. N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.-C., Cui, G., Micevic, G., Perales, J. C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.012 · Cited by 1,462
The SLC2 (GLUT) family of membrane transporters
Mueckler, M., & Thorens, B. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.001 · Cited by 1,328 · cited 1×
“Among them, GLUT1, GLUT2 (SLC2A2), GLUT3 (SLC2A3), and GLUT4 (SLC2A4) are the four most well-known subtypes, which have distinct regulatory mechanisms and kinetic characteristic and each subtype plays a specific function in maintaining cellular and organismal glucose homeostasis [29,30].”
BackgroundFoxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments
Angelin, A., Gil-de-Gómez, L., Dahiya, S., Jiao, J., Guo, L., Levine, M. H., Wang, Z., Quinn, W. J., Kopinski, P. K., Wang, L., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.12.018 · Cited by 1,246 · cited 1×
“Treg cells can maintain their function by oxidizing lactate [19].”
BackgroundProtein O-GlcNAcylation: emerging mechanisms and functions
Yang, X., & Qian, K. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.22 · Cited by 1,194
Anastasiou, D., Poulogiannis, G., Asara, J. M., Boxer, M. B., Jiang, J.-K., Shen, M., Bellinger, G., Sasaki, A. T., Locasale, J. W., Auld, D. S., et al. (2011) · Science · doi:10.1126/science.1211485 · Cited by 1,190
Targeting lactate metabolism for cancer therapeutics
Doherty, J. R., & Cleveland, J. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci69741 · Cited by 1,166
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153
Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function
Wilson, J. E. (2003) · Journal of Experimental Biology · doi:10.1242/jeb.00241 · Cited by 1,085 · cited 2×
“The autocatalytic product G-6-P mediates feedback inhibition of HK1, HK2, and HK3 activity, and G-6-P induces conformational changes in HK1 and HK2 that separate them from the mitochondria [99,100].”
BackgroundGlucose transporters in the 21st Century
Thorens, B., & Mueckler, M. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00712.2009 · Cited by 1,013 · cited 1×
“Among them, GLUT1, GLUT2 (SLC2A2), GLUT3 (SLC2A3), and GLUT4 (SLC2A4) are the four most well-known subtypes, which have distinct regulatory mechanisms and kinetic characteristic and each subtype plays a specific function in maintaining cellular and organismal glucose homeostasis [29,30].”
BackgroundTargeting cellular metabolism to improve cancer therapeutics
Zhao, Y., Butler, E. B., & Tan, M. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.60 · Cited by 989
Patra, K. C., Wang, Q., Bhaskar, P. T., Miller, L., Wang, Z., Wheaton, W., Chandel, N., Laakso, M., Muller, W. J., Allen, E. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.014 · Cited by 853
Husain, Z., Huang, Y., Seth, P., & Sukhatme, V. P. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202702 · Cited by 822
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis
Anastasiou, D., Yu, Y., Israelsen, W. J., Jiang, J.-K., Boxer, M. B., Hong, B. S., Tempel, W., Dimov, S., Shen, M., Jha, A., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1060 · Cited by 816
Wolf, A., Agnihotri, S., Micallef, J., Mukherjee, J., Sabha, N., Cairns, R., Hawkins, C., & Guha, A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101470 · Cited by 789
Navigating metabolic pathways to enhance antitumour immunity and immunotherapy
Li, X., Wenes, M., Romero, P., Huang, S. C.-C., Fendt, S.-M., & Ho, P.-C. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0203-7 · Cited by 733
Metabolic Reprogramming: the Emerging Concept and Associated Therapeutic Strategies
Yoshida, G. J. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0221-y · Cited by 716 · cited 1×
“Therefore, metabolic reprogramming of glucose metabolism is considered the essential hallmark of tumorigenesis and development [26].”
BackgroundLactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy
Feng, Y., Xiong, Y., Qiao, T., Li, X., Jia, L., & Han, Y. (2018) · Cancer Medicine · doi:10.1002/cam4.1820 · Cited by 705
San-Millán, I., & Brooks, G. A. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw127 · Cited by 610
2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents
Pajak, B., Siwiak, E., Sołtyka, M., Priebe, A., Zieliński, R., Fokt, I., Ziemniak, M., Jaśkiewicz, A., Borowski, R., Domoradzki, T., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010234 · Cited by 574
Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality
Chan, D. A., Sutphin, P. D., Nguyen, P., Turcotte, S., Lai, E. W., Banh, A., Reynolds, G. E., Chi, J.-T., Wu, J., Solow-Cordero, D. E., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002394 · Cited by 557 · cited 1×
“[42] first found that STF-31 (Figure 3B) could inhibit the growth of renal cancer cells by directly binding to GLUT1 to inhibit glucose uptake.”
BackgroundLiu, Y., Cao, Y., Zhang, W., Bergmeier, S., Qian, Y., Akbar, H., Colvin, R., Ding, J., Tong, L., Wu, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0131 · Cited by 555
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells
Israelsen, W. J., Dayton, T. L., Davidson, S. M., Fiske, B. P., Hosios, A. M., Bellinger, G., Li, J., Yu, Y., Sasaki, M., Horner, J. W., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.025 · Cited by 549
Raez, L. E., Papadopoulos, K., Ricart, A. D., Chiorean, E. G., DiPaola, R. S., Stein, M. N., Rocha Lima, C. M., Schlesselman, J. J., Tolba, K., Langmuir, V. K., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2045-1 · Cited by 543
DeWaal, D., Nogueira, V., Terry, A. R., Patra, K. C., Jeon, S.-M., Guzman, G., Au, J., Long, C. P., Antoniewicz, M. R., & Hay, N. (2018) · Nature Communications · doi:10.1038/s41467-017-02733-4 · Cited by 525
Lactate: A Metabolic Driver in the Tumour Landscape
Ippolito, L., Morandi, A., Giannoni, E., & Chiarugi, P. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.10.011 · Cited by 523 · cited 5×
“Such cancer cells with different metabolic patterns exhibit a phenomenon known as metabolic symbiosis, which makes cancer cells more adaptable to the harsh TME [23].”
BackgroundInfluentialShikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2
Chen, J., Xie, J., Jiang, Z., Wang, B., Wang, Y., & Hu, X. (2011) · Oncogene · doi:10.1038/onc.2011.137 · Cited by 512
Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake
Flavahan, W. A., Wu, Q., Hitomi, M., Rahim, N., Kim, Y., Sloan, A. E., Weil, R. J., Nakano, I., Sarkaria, J. N., Stringer, B. W., et al. (2013) · Nature Neuroscience · doi:10.1038/nn.3510 · Cited by 510 · cited 1×
“The Warburg effect promotes the glucose uptake of cancer cells in the tumor microenvironment [6].”
BackgroundPyruvate Kinase M2 and Cancer: The Role of PKM2 in Promoting Tumorigenesis
Zahra, K., Dey, T., Ashish, Mishra, S. P., & Pandey, U. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00159 · Cited by 501
Targeting mutant p53 for cancer therapy: direct and indirect strategies
Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., Shen, J., Cai, L., Cai, X., & Chen, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01169-0 · Cited by 483
Gong, Y., Ji, P., Yang, Y.-S., Xie, S., Yu, T.-J., Xiao, Y., Jin, M.-L., Ma, D., Guo, L.-W., Pei, Y.-C., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.012 · Cited by 467
2-Deoxy-D-glucose targeting of glucose metabolism in cancer cells as a potential therapy
Zhang, D., Li, J., Wang, F., Hu, J., Wang, S., & Sun, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.003 · Cited by 462
Expression of glucose transporters in cancers
Szablewski, L. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.12.004 · Cited by 452
Maschek, G., Savaraj, N., Priebe, W., Braunschweiger, P., Hamilton, K., Tidmarsh, G. F., De Young, L. R., & Lampidis, T. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3294 · Cited by 451
Inhibition of the intestinal glucose transporter GLUT2 by flavonoids
Kwon, O., Eck, P., Chen, S., Corpe, C. P., Lee, J., Kruhlak, M., & Levine, M. (2007) · The FASEB Journal · doi:10.1096/fj.06-6620com · Cited by 450
Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment
Barron, C. C., Bilan, P. J., Tsakiridis, T., & Tsiani, E. (2016) · Metabolism · doi:10.1016/j.metabol.2015.10.007 · Cited by 435 · cited 2×
“Multiple myeloma mainly expresses GLUT4, which is responsible for maintaining adequate glucose uptake [33,38].”
BackgroundPhosphoglycerate Mutase 1 Coordinates Glycolysis and Biosynthesis to Promote Tumor Growth
Hitosugi, T., Zhou, L., Elf, S., Fan, J., Kang, H.-B., Seo, J. H., Shan, C., Dai, Q., Zhang, L., Xie, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.020 · Cited by 432
Clem, B., Telang, S., Clem, A., Yalcin, A., Meier, J., Simmons, A., Rasku, M. A., Arumugam, S., Dean, W. L., Eaton, J., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0482 · Cited by 432
Mannose impairs tumour growth and enhances chemotherapy
Gonzalez, P. S., O’Prey, J., Cardaci, S., Barthet, V. J. A., Sakamaki, J.-I., Beaumatin, F., Roseweir, A., Gay, D. M., Mackay, G., Malviya, G., et al. (2018) · Nature · doi:10.1038/s41586-018-0729-3 · Cited by 428 · cited 1×
“The uptake of hexoses, such as fructose and mannose, is also significantly increased in cancers as a result of rapid glucose depletion, with GLUT5 specifically transporting fructose in lymphomas and mannose sharing a transport enzyme with glucose [39,40].”
BackgroundTian, H., Zhang, T., Qin, S., Huang, Z., Zhou, L., Shi, J., Nice, E. C., Xie, N., Huang, C., & Shen, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01320-5 · Cited by 426
Self-citationRegulation of glucose metabolism by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatases in cancer
Yalcin, A., Telang, S., Clem, B., & Chesney, J. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.003 · Cited by 405
Zhou, M., Zhao, Y., Ding, Y., Liu, H., Liu, Z., Fodstad, O., Riker, A. I., Kamarajugadda, S., Lu, J., Owen, L. B., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-33 · Cited by 395
CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours
Zappasodi, R., Serganova, I., Cohen, I. J., Maeda, M., Shindo, M., Senbabaoglu, Y., Watson, M. J., Leftin, A., Maniyar, R., Verma, S., et al. (2021) · Nature · doi:10.1038/s41586-021-03326-4 · Cited by 393
Hu, H., Juvekar, A., Lyssiotis, C. A., Lien, E. C., Albeck, J. G., Oh, D., Varma, G., Hung, Y. P., Ullas, S., Lauring, J., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.042 · Cited by 380
Glucose Catabolism in Cancer Cells
Mathupala, S. P., Rempel, A., & Pedersen, P. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108181200 · Cited by 373
Role of monocarboxylate transporters in human cancers: state of the art
Pinheiro, C., Longatto-Filho, A., Azevedo-Silva, J., Casal, M., Schmitt, F. C., & Baltazar, F. (2012) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-012-9428-1 · Cited by 368
Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release
Goetze, K. (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.1055 · Cited by 355
18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response
Ben-Haim, S., & Ell, P. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.054205 · Cited by 351
Passenger deletions generate therapeutic vulnerabilities in cancer
Muller, F. L., Colla, S., Aquilanti, E., Manzo, V. E., Genovese, G., Lee, J., Eisenson, D., Narurkar, R., Deng, P., Nezi, L., et al. (2012) · Nature · doi:10.1038/nature11331 · Cited by 339
Biological Role and Therapeutic Potential of IDH Mutations in Cancer
Waitkus, M. S., Diplas, B. H., & Yan, H. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.011 · Cited by 335
Mitochondria and cancer chemoresistance
Guerra, F., Arbini, A. A., & Moro, L. (2017) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2017.01.012 · Cited by 323
Targeting mitochondrial metabolism for precision medicine in cancer
Sainero-Alcolado, L., Liaño-Pons, J., Ruiz-Pérez, M. V., & Arsenian-Henriksson, M. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-01022-y · Cited by 322
Metabolic interventions in the immune response to cancer
O’Sullivan, D., Sanin, D. E., Pearce, E. J., & Pearce, E. L. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0140-9 · Cited by 312
Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint Therapy
Renner, K., Bruss, C., Schnell, A., Koehl, G., Becker, H. M., Fante, M., Menevse, A.-N., Kauer, N., Blazquez, R., Hacker, L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.068 · Cited by 306
PKM2 methylation by CARM1 activates aerobic glycolysis to promote tumorigenesis
Liu, F., Ma, F., Wang, Y., Hao, L., Zeng, H., Jia, C., Wang, Y., Liu, P., Ong, I. M., Li, B., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3630 · Cited by 305
Self-citationThe hypoxia–lactate axis tempers inflammation
Ivashkiv, L. B. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0259-8 · Cited by 305 · cited 1×
“Lactate participates in the homeostatic regulation of M1 macrophages [20] and inhibits CD8+ T cells and natural killer cells (NK cells) from producing γ-interferon [21], which in turn maintains an immunosuppressive microenvironment [22,23].”
BackgroundGLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
Wu, Q., ba-alawi, W., Deblois, G., Cruickshank, J., Duan, S., Lima-Fernandes, E., Haight, J., Tonekaboni, S. A. M., Fortier, A.-M., Kuasne, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18020-8 · Cited by 305 · cited 1×
“BAY-876 inhibited GLUT1 with good metabolic stability in vitro, had a high oral bioavailability in vivo, and its anticancer activity was demonstrated in a variety of cancers, including ovarian and triple-negative breast cancer [50,51].”
BackgroundIdentification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY‐876
Siebeneicher, H., Cleve, A., Rehwinkel, H., Neuhaus, R., Heisler, I., Müller, T., Bauser, M., & Buchmann, B. (2016) · ChemMedChem · doi:10.1002/cmdc.201600276 · Cited by 294
Shi, L., Pan, H., Liu, Z., Xie, J., & Han, W. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.44 · Cited by 292
Fu, Q.-F., Liu, Y., Fan, Y., Hua, S.-N., Qu, H.-Y., Dong, S.-W., Li, R.-L., Zhao, M.-Y., Zhen, Y., Yu, X.-L., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0117-5 · Cited by 286
Tian, H., Zhang, M., Jin, G., Jiang, Y., & Luan, Y. (2021) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2020.12.028 · Cited by 283
Clinical role of positron emission tomography in oncology
Bomanji, J., Costa, D., & Ell, P. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00257-6 · Cited by 281
Protein profiles associated with survival in lung adenocarcinoma
Chen, G., Gharib, T. G., Wang, H., Huang, C.-C., Kuick, R., Thomas, D. G., Shedden, K. A., Misek, D. E., Taylor, J. M. G., Giordano, T. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2233850100 · Cited by 277
Self-citationYang, X., Lu, Y., Hang, J., Zhang, J., Zhang, T., Huo, Y., Liu, J., Lai, S., Luo, D., Wang, L., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0111 · Cited by 277
Targeting 6-Phosphofructo-2-Kinase (PFKFB3) as a Therapeutic Strategy against Cancer
Clem, B. F., O'Neal, J., Tapolsky, G., Clem, A. L., Imbert-Fernandez, Y., Kerr, D. A., Klarer, A. C., Redman, R., Miller, D. M., Trent, J. O., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0097 · Cited by 276
Acetylation of PGK1 promotes liver cancer cell proliferation and tumorigenesis
Hu, H., Zhu, W., Qin, J., Chen, M., Gong, L., Li, L., Liu, X., Tao, Y., Yin, H., Zhou, H., et al. (2017) · Hepatology · doi:10.1002/hep.28887 · Cited by 269
Pyruvate kinase M2 (PKM2) in cancer and cancer therapeutics
Zhu, S., Guo, Y., Zhang, X., Liu, H., Yin, M., Chen, X., & Peng, C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.11.018 · Cited by 266
Ždralević, M., Brand, A., Di Ianni, L., Dettmer, K., Reinders, J., Singer, K., Peter, K., Schnell, A., Bruss, C., Decking, S.-M., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004180 · Cited by 255
Simons, A. L., Ahmad, I. M., Mattson, D. M., Dornfeld, K. J., & Spitz, D. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3717 · Cited by 238
Stein, E. M., DiNardo, C. D., Fathi, A. T., Mims, A. S., Pratz, K. W., Savona, M. R., Stein, A. S., Stone, R. M., Winer, E. S., Seet, C. S., et al. (2021) · Blood · doi:10.1182/blood.2020007233 · Cited by 232 · cited 1×
“A few of them, such as ivosidenib and enasidenib, have been successfully translated into clinical applications for cancer treatment [27].”
BackgroundGlucose Catabolism in Cancer Cells
Mathupala, S. P., Heese, C., & Pedersen, P. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22776 · Cited by 231
Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling
Evans, M. J., Saghatelian, A., Sorensen, E. J., & Cravatt, B. F. (2005) · Nature Biotechnology · doi:10.1038/nbt1149 · Cited by 230
Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression
Goldberg, M. S., & Sharp, P. A. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111487 · Cited by 230
Chen, W.-L., Wang, Y.-Y., Zhao, A., Xia, L., Xie, G., Su, M., Zhao, L., Liu, J., Qu, C., Wei, R., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.006 · Cited by 227 · cited 1×
“The uptake of hexoses, such as fructose and mannose, is also significantly increased in cancers as a result of rapid glucose depletion, with GLUT5 specifically transporting fructose in lymphomas and mannose sharing a transport enzyme with glucose [39,40].”
BackgroundUnlocking the Potential of HK2 in Cancer Metabolism and Therapeutics
Garcia, S. N., Guedes, R. C., & Marques, M. M. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867326666181213092652 · Cited by 227
Targeting metabolism with a ketogenic diet during the treatment of glioblastoma multiforme
Champ, C. E., Palmer, J. D., Volek, J. S., Werner-Wasik, M., Andrews, D. W., Evans, J. J., Glass, J., Kim, L., & Shi, W. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1362-0 · Cited by 224
Shikonin derivatives for cancer prevention and therapy
Boulos, J. C., Rahama, M., Hegazy, M.-E. F., & Efferth, T. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.04.033 · Cited by 221
Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis
Ohshima, K., & Morii, E. (2021) · Metabolites · doi:10.3390/metabo11010028 · Cited by 220
Kapoor, K., Finer-Moore, J. S., Pedersen, B. P., Caboni, L., Waight, A., Hillig, R. C., Bringmann, P., Heisler, I., Müller, T., Siebeneicher, H., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603735113 · Cited by 213 · cited 2×
“esters [60], pyrazolo-pyrimidines [37], quinazolines [61], phenylalanine amides [62] and many more [35,58,63–67], EF24 [59], ketoximes [36], polyphenolic esters [60], pyrazolopyrimidines [37], quinazolines [61], phenylalanine amides [62], and many more [63–67], have emerged but need to be more deeply investigated.”
BackgroundPrinciple and design of pseudo-natural products
Karageorgis, G., Foley, D. J., Laraia, L., & Waldmann, H. (2020) · Nature Chemistry · doi:10.1038/s41557-019-0411-x · Cited by 213
Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy
Zambrano, A., Molt, M., Uribe, E., & Salas, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133374 · Cited by 210 · cited 1×
“In addition, natural products such as trehalose (Figure 3K) [78], silibinin (Figure 3L) [79], curcumin (Figure 3M) [80], resveratrol (Figure 3N) [81], naringenin [82], quercetin [83], isoquercetin [84], kaempferol [85], xanthohumol [86], caffeine [87], bezielle [88], theophylline [89], (+)-Cryptocaryone [90], and mela…”
BackgroundMethyl jasmonate binds to and detaches mitochondria-bound hexokinase
Goldin, N., Arzoine, L., Heyfets, A., Israelson, A., Zaslavsky, Z., Bravman, T., Bronner, V, Notcovich, A., Shoshan-Barmatz, V, & Flescher, E. (2008) · Oncogene · doi:10.1038/onc.2008.108 · Cited by 208
Mechanism of antineoplastic activity of lonidamine
Nath, K., Guo, L., Nancolas, B., Nelson, D. S., Shestov, A. A., Lee, S.-C., Roman, J., Zhou, R., Leeper, D. B., Halestrap, A. P., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.08.001 · Cited by 205
Bola, B. M., Chadwick, A. L., Michopoulos, F., Blount, K. G., Telfer, B. A., Williams, K. J., Smith, P. D., Critchlow, S. E., & Stratford, I. J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-1091 · Cited by 203
Glucose Transporters as a Target for Anticancer Therapy
Pliszka, M., & Szablewski, L. (2021) · Cancers · doi:10.3390/cancers13164184 · Cited by 199 · cited 1×
“Therefore, STF-31 is non-toxic to normal tissues and can selectively kill cancer cells [43,44].”
BackgroundLi, F.-L., Liu, J.-P., Bao, R.-X., Yan, G., Feng, X., Xu, Y.-P., Sun, Y.-P., Yan, W., Ling, Z.-Q., Xiong, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02950-5 · Cited by 196
A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death
Wood, T. E., Dalili, S., Simpson, C. D., Hurren, R., Mao, X., Saiz, F. S., Gronda, M., Eberhard, Y., Minden, M. D., Bilan, P. J., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0569 · Cited by 195
Belzacq, A.-S., El Hamel, C., Vieira, H. L. A., Cohen, I., Haouzi, D., Métivier, D., Marchetti, P., Brenner, C., & Kroemer, G. (2001) · Oncogene · doi:10.1038/sj.onc.1204953 · Cited by 194
Li, B., Jiang, J., Assaraf, Y. G., Xiao, H., Chen, Z.-S., & Huang, C. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100720 · Cited by 188
Self-citationMetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway
Yu, T., Zhao, Y., Hu, Z., Li, J., Chu, D., Zhang, J., Li, Z., Chen, B., Zhang, X., Pan, H., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0671 · Cited by 182
Maftouh, M., Avan, A., Sciarrillo, R., Granchi, C., Leon, L. G., Rani, R., Funel, N., Smid, K., Honeywell, R., Boggi, U., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.681 · Cited by 180
Siddiqui, F. A., Prakasam, G., Chattopadhyay, S., Rehman, A. U., Padder, R. A., Ansari, M. A., Irshad, R., Mangalhara, K. C., Bamezai, R. N. K., Husain, M., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-25524-3 · Cited by 173
Zhang, H.-N., Yang, L., Ling, J.-Y., Czajkowsky, D. M., Wang, J.-F., Zhang, X.-W., Zhou, Y.-M., Ge, F., Yang, M.-K., Xiong, Q., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521316112 · Cited by 168
PKM2 Inhibitor Shikonin Overcomes the Cisplatin Resistance in Bladder Cancer by Inducing Necroptosis
Wang, Y., Hao, F., Nan, Y., Qu, L., Na, W., Jia, C., & Chen, X. (2018) · International Journal of Biological Sciences · doi:10.7150/ijbs.27854 · Cited by 168
Kotowski, K. W., Rosik, J., Machaj, F., Supplitt, S., Wiczew, D., Jabłońska, K., Wiecheć, E., Ghavami, S., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13040909 · Cited by 167
Lonidamine: Efficacy and safety in clinical trials for the treatment of solid tumors
Di Cosimo, S., Ferretti, G., Papaldo, P., Carlini, P., Fabi, A., & Cognetti, F. (2003) · Drugs of Today · doi:10.1358/dot.2003.39.3.799451 · Cited by 166
Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death
Li, S., Li, J., Dai, W., Zhang, Q., Feng, J., Wu, L., Liu, T., Yu, Q., Xu, S., Wang, W., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.323 · Cited by 166
PGK1-mediated cancer progression and drug resistance.
He, Y., Yang, L., Zhang, D., Wang, X., Zhang, P., Li, H., Ejaz, S., & Liang, S. (2019) · PubMed · Cited by 166
Glycolytic enzyme inhibitors in cancer treatment
Scatena, R., Bottoni, P., Pontoglio, A., Mastrototaro, L., & Giardina, B. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.10.1533 · Cited by 164
Fang, Y., Liu, W., Tang, Z., Ji, X., Zhou, Y., Song, S., Tian, M., Tao, C., Huang, R., Zhu, G., et al. (2023) · Hepatology · doi:10.1002/hep.32348 · Cited by 162
Melstrom, L. G., Salabat, M. R., Ding, X.-Z., Milam, B. M., Strouch, M. J., Pelling, J. C., & Bentrem, D. J. (2008) · Pancreas · doi:10.1097/mpa.0b013e3181735ccb · Cited by 159
Farabegoli, F., Vettraino, M., Manerba, M., Fiume, L., Roberti, M., & Di Stefano, G. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.08.012 · Cited by 158
Targeting the Warburg effect via LDHA inhibition engages ATF 4 signaling for cancer cell survival
Pathria, G., Scott, D. A., Feng, Y., Sang Lee, J., Fujita, Y., Zhang, G., Sahu, A. D., Ruppin, E., Herlyn, M., Osterman, A. L., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201899735 · Cited by 156
Zhang, T., Zhu, X., Wu, H., Jiang, K., Zhao, G., Shaukat, A., Deng, G., & Qiu, C. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14276 · Cited by 156
2-Deoxy-d-glucose causes cytotoxicity, oxidative stress, and radiosensitization in pancreatic cancer
Coleman, M. C., Asbury, C., Daniels, D. H., Du, J., Aykin‐Burns, N., Smith, B. J., Li, L., Spitz, D. R., & Cullen, J. J. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.08.032 · Cited by 153
GSH-Responsive Nanoprodrug to Inhibit Glycolysis and Alleviate Immunosuppression for Cancer Therapy
Liu, X., Li, Y., Wang, K., Chen, Y., Shi, M., Zhang, X., Pan, W., Li, N., & Tang, B. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c03089 · Cited by 153
Capello, M., Ferri-Borgogno, S., Riganti, C., Chattaragada, M. S., Principe, M., Roux, C., Zhou, W., Petricoin, E. F., Cappello, P., & Novelli, F. (2016) · Oncotarget · doi:10.18632/oncotarget.6798 · Cited by 152
Mondal, S., Roy, D., Sarkar Bhattacharya, S., Jin, L., Jung, D., Zhang, S., Kalogera, E., Staub, J., Wang, Y., Xuyang, W., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.31868 · Cited by 151
Yu, J., Wei, Z., Li, Q., Wan, F., Chao, Z., Zhang, X., Li, L., Meng, H., & Tian, L. (2021) · Advanced Science · doi:10.1002/advs.202101467 · Cited by 151
Self-citationPértega‐Gomes, N., Felisbino, S. L., Massie, C. E., Vizcaino, J. R., Coelho, R., Sandi, C., Simoes‐Sousa, S., Jurmeister, S., Ramos‐Montoya, A., Asim, M., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4547 · Cited by 150
Electrospun fiber mats containing shikonin and derivatives with potential biomedical applications
Kontogiannopoulos, K. N., Assimopoulou, A. N., Tsivintzelis, I., Panayiotou, C. G., & Papageorgiou, V. P. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.02.004 · Cited by 149
Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer
Qian, X., Xu, W., Xu, J., Shi, Q., Li, J., Weng, Y., Jiang, Z., Feng, L., Wang, X., Zhou, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17868 · Cited by 149
Natural Product Micheliolide (MCL) Irreversibly Activates Pyruvate Kinase M2 and Suppresses Leukemia
Li, J., Li, S., Guo, J., Li, Q., Long, J., Ma, C., Ding, Y., Yan, C., Li, L., Wu, Z., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00241 · Cited by 147
Self-citationRen, F., Wu, H., Lei, Y., Zhang, H., Liu, R., Zhao, Y., Chen, X., Zeng, D., Tong, A., Chen, L., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-81 · Cited by 145
Self-citationMa, Y., Wang, W., Idowu, M. O., Oh, U., Wang, X.-Y., Temkin, S. M., & Fang, X. (2018) · Cancers · doi:10.3390/cancers11010033 · Cited by 145 · cited 1×
“BAY-876 inhibited GLUT1 with good metabolic stability in vitro, had a high oral bioavailability in vivo, and its anticancer activity was demonstrated in a variety of cancers, including ovarian and triple-negative breast cancer [50,51].”
BackgroundGenistein downregulates onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells
Hirata, H., Ueno, K., Nakajima, K., Tabatabai, Z. L., Hinoda, Y., Ishii, N., & Dahiya, R. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.173 · Cited by 143 · cited 1×
“Moreover, as a GLUT inhibitor, genistein can regulate miR-1260b to affect the Wnt signaling pathway to inhibit cancer tissue growth and metastasis [70].”
BackgroundMelatonin uptake through glucose transporters: a new target for melatonin inhibition of cancer
Hevia, D., González‐Menéndez, P., Quiros‐González, I., Miar, A., Rodríguez‐García, A., Tan, D., Reiter, R. J., Mayo, J. C., & Sainz, R. M. (2015) · Journal of Pineal Research · doi:10.1111/jpi.12210 · Cited by 143 · cited 1×
“In addition, natural products such as trehalose (Figure 3K) [78], silibinin (Figure 3L) [79], curcumin (Figure 3M) [80], resveratrol (Figure 3N) [81], naringenin [82], quercetin [83], isoquercetin [84], kaempferol [85], xanthohumol [86], caffeine [87], bezielle [88], theophylline [89], (+)-Cryptocaryone [90], and mela…”
BackgroundBeloueche-Babari, M., Casals Galobart, T., Delgado-Goni, T., Wantuch, S., Parkes, H. G., Tandy, D., Harker, J. A., & Leach, M. O. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0717-x · Cited by 143
Geschwind, J.-F., Georgiades, C. S., Ko, Y. H., & Pedersen, P. L. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.3.449 · Cited by 141
Wei, L., Zhou, Y., Dai, Q., Qiao, C., Zhao, L., Hui, H., Lu, N., & Guo, Q.-L. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.131 · Cited by 140
Self-citationBenserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2
Li, W., Zheng, M., Wu, S., Gao, S., Yang, M., Li, Z., Min, Q., Sun, W., Chen, L., Xiang, G., et al. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0530-4 · Cited by 140
Vitamin K: Redox-modulation, prevention of mitochondrial dysfunction and anticancer effect
Ivanova, D., Zhelev, Z., Getsov, P. G., Nikolova, B., Aoki, I., Higashi, T., & Bakalova, R. (2018) · Redox Biology · doi:10.1016/j.redox.2018.03.013 · Cited by 137
Karageorgis, G., Reckzeh, E. S., Ceballos, J., Schwalfenberg, M., Sievers, S., Ostermann, C., Pahl, A., Ziegler, S., & Waldmann, H. (2018) · Nature Chemistry · doi:10.1038/s41557-018-0132-6 · Cited by 137
Gao, C., Hou, G., Liu, J., Ru, T., Xu, Y., Zhao, S., Ye, H., Zhang, L., Chen, K., Guo, Y., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201912489 · Cited by 136
Lactic dehydrogenase and cancer an overview
Naviglio, S. (2015) · Frontiers in bioscience · doi:10.2741/4368 · Cited by 135
IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo
Venkatanarayan, A., Raulji, P., Norton, W., Chakravarti, D., Coarfa, C., Su, X., Sandur, S. K., Ramirez, M. S., Lee, J., Kingsley, C. V., et al. (2015) · Nature · doi:10.1038/nature13910 · Cited by 130
Cao, M., Isaac, R., Yan, W., Ruan, X., Jiang, L., Wan, Y., Wang, J., Wang, E., Caron, C., Neben, S., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00919-7 · Cited by 130
Dai, W., Wang, F., Lu, J., Xia, Y., He, L., Chen, K., Li, J., Li, S., Liu, T., Zheng, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3800 · Cited by 128
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis
Chesney, J. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000241661.15514.fb · Cited by 128
Azevedo, C., Correia‐Branco, A., Araújo, J. R., Guimarães, J. T., Keating, E., & Martel, F. (2015) · Nutrition and Cancer · doi:10.1080/01635581.2015.1002625 · Cited by 127 · cited 1×
“In addition, natural products such as trehalose (Figure 3K) [78], silibinin (Figure 3L) [79], curcumin (Figure 3M) [80], resveratrol (Figure 3N) [81], naringenin [82], quercetin [83], isoquercetin [84], kaempferol [85], xanthohumol [86], caffeine [87], bezielle [88], theophylline [89], (+)-Cryptocaryone [90], and mela…”
BackgroundDiscovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor
Cho, Y. S., Levell, J. R., Liu, G., Caferro, T. R., Sutton, J. C., Shafer, C. M., Costales, A., Manning, J. R., Zhao, Q. L., Sendzik, M., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00342 · Cited by 127
Wu, K.-H., Ho, C., Chen, Z.-F., Chen, L.-C., Whang‐Peng, J., Lin, T., & Ho, Y. (2017) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2017.03.009 · Cited by 126
Lactoferrin functionalized PEG-PLGA nanoparticles of shikonin for brain targeting therapy of glioma
Li, H., Tong, Y., Bai, L., Ye, L., Zhong, L., Duan, X., & Zhu, Y. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.08.155 · Cited by 125
Kim, E.-Y., Chung, T.-W., Han, C. W., Park, S. Y., Park, K. H., Jang, S. B., & Ha, K.-T. (2019) · Scientific Reports · doi:10.1038/s41598-019-40617-3 · Cited by 125
3‐Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs
Ihrlund, L. S., Hernlund, E., Khan, O. M., & Shoshan, M. C. (2008) · Molecular Oncology · doi:10.1016/j.molonc.2008.01.003 · Cited by 124
Targeting PFKFB3 radiosensitizes cancer cells and suppresses homologous recombination
Gustafsson, N. M. S., Färnegårdh, K., Bonagas, N., Ninou, A. H., Groth, P., Wiita, E., Jönsson, M., Hallberg, K., Lehto, J., Pennisi, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06287-x · Cited by 124
Draoui, N., Schicke, O., Seront, E., Bouzin, C., Sonveaux, P., Riant, O., & Feron, O. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0653 · Cited by 123
Huang, T., Feng, Q., Wang, Z., Li, W., Sun, Z., Wilhelm, J., Huang, G., Vo, T., Sumer, B. D., & Gao, J. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202000549 · Cited by 121
A Unique Small Molecule Inhibitor of Enolase Clarifies Its Role in Fundamental Biological Processes
Jung, D., Kim, W., Park, S.-H., Lee, J., Kim, J., Su, D., Ha, H., Chang, Y., & Williams, D. R. (2013) · ACS Chemical Biology · doi:10.1021/cb300687k · Cited by 119
Ning, X., Qi, H., Li, R., Li, Y., Jin, Y., McNutt, M. A., Liu, J., & Yin, Y. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.064 · Cited by 119
Silybin and dehydrosilybin decrease glucose uptake by inhibiting GLUT proteins
Zhan, T., Digel, M., Kuech, E., Stremmel, W., & Füllekrug, J. (2010) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22984 · Cited by 117 · cited 1×
“In addition, natural products such as trehalose (Figure 3K) [78], silibinin (Figure 3L) [79], curcumin (Figure 3M) [80], resveratrol (Figure 3N) [81], naringenin [82], quercetin [83], isoquercetin [84], kaempferol [85], xanthohumol [86], caffeine [87], bezielle [88], theophylline [89], (+)-Cryptocaryone [90], and mela…”
BackgroundOjelabi, O., Lloyd, K. P., Simon, A. H., Zutter, J. K. D., & Carruthers, A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.759175 · Cited by 115
PKM2 is the target of proanthocyanidin B2 during the inhibition of hepatocellular carcinoma
Feng, J., Wu, L., Ji, J., Chen, K., Yu, Q., Zhang, J., Chen, J., Mao, Y., Wang, F., Dai, W., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1194-z · Cited by 114
Chang, Y., Chiou, J., Yang, Y.-F., Su, C., Lin, Y., Yang, C.-N., Lu, P., Huang, M., Yang, C.-J., & Hsiao, M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-4080 · Cited by 114
Hitosugi, T., Zhou, L., Fan, J., Elf, S., Zhang, L., Xie, J., Wang, Y., Gu, T.-L., Alečković, M., LeRoy, G., et al. (2013) · Nature Communications · doi:10.1038/ncomms2759 · Cited by 113
New Advances in Biomedical Application of Polymeric Micelles
Figueiras, A., Domingues, C., Jarak, I., Santos, A. I., Parra, A., Pais, A. A. C. C., Alvarez‐Lorenzo, C., Concheiro, Á., Kabanov, A. V., Cabral, H., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081700 · Cited by 112
Martin, S. P., Fako, V. E., Dang, H. T., Dominguez, D. A., Khatib, S. A., Ma, L., Wang, H., Zheng, W., & Wang, X. W. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01605-y · Cited by 109
PKM2, a potential target for regulating cancer
Li, Y., Li, X., Liu, J., Wang, H., Fan, L., Li, J., & Sun, G. (2018) · Gene · doi:10.1016/j.gene.2018.05.038 · Cited by 107
Synthesis of Indomorphan Pseudo‐Natural Product Inhibitors of Glucose Transporters GLUT‐1 and ‐3
Ceballos, J., Schwalfenberg, M., Karageorgis, G., Reckzeh, E. S., Sievers, S., Ostermann, C., Pahl, A., Sellstedt, M., Nowacki, J., Corrales, M. A. C., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201909518 · Cited by 107
Jing, Q., Ruan, H., Li, J., Wang, Z., Pei, L., Hu, H., He, Z., Wu, T. S., Ruan, S., Guo, T., et al. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121142 · Cited by 106
Self-citationLi, W., Ma, X., Li, N., Liu, H., Dong, Q., Zhang, J., Yang, C., Liu, Y., Liang, Q., Zhang, S., et al. (2016) · Experimental Cell Research · doi:10.1016/j.yexcr.2016.11.002 · Cited by 103
Qi, H., Ning, X., Yu, C., Ji, X., Jin, Y., McNutt, M. A., & Yin, Y. (2019) · Cell Death and Disease · doi:10.1038/s41419-018-1271-9 · Cited by 103
Tao, T., Su, Q., Xu, S., Deng, J., Zhou, S., Yu, Z., Huang, Y., He, C., He, S., Peng, M., et al. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27129 · Cited by 102
Targeting T Cell Activation and Lupus Autoimmune Phenotypes by Inhibiting Glucose Transporters
Li, W., Qu, G., Choi, S.-C., Cornaby, C., Titov, A., Kanda, N., Teng, X., Wang, H., & Morel, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00833 · Cited by 100 · cited 1×
“CG-5 is a thiazolidinedione derivative that inhibits GLUT, blocks glucose transport in T cells, and inhibits glycolysis, thus inhibiting the differentiation of Th1 and Th17 cells, inducing differentiated Treg cells, and suppressing the proliferation of CD4+ T cells [52].”
BackgroundZheng, M., Wu, C., Yang, K., Yang, Y., Liu, Y., Gao, S., Wang, Q., Li, C., Chen, L., & Li, H. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105367 · Cited by 100
Vaughan, R. A., Garcia‐Smith, R., Dorsey, J., Griffith, J. K., Bisoffi, M., & Trujillo, K. A. (2013) · International Journal of Cancer · doi:10.1002/ijc.28264 · Cited by 99
Wu, H., Wang, Y., Wu, C., Yang, P., Li, H., & Li, Z. (2016) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b04549 · Cited by 99
Melstrom, L. G., Salabat, M. R., Ding, X.-Z., Strouch, M. J., Grippo, P. J., Mirzoeva, S., Pelling, J. C., & Bentrem, D. J. (2011) · Journal of Surgical Research · doi:10.1016/j.jss.2010.10.041 · Cited by 98
Ždralević, M., Vučetić, M., Daher, B., Marchiq, I., Parks, S. K., & Pouysségur, J. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.12.002 · Cited by 98
Lin, S.-T., Tu, S., Yang, P., Hsu, S., Lee, W., Ho, C., Wu, C., Lai, Y.-H., Chen, M., & Chen, L.-C. (2016) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6b02861 · Cited by 96 · cited 1×
“Additionally, phloretin can inhibit GLUT1, which is overexpressed in the hypoxic area of resistant colon cancer cell lines, and induce apoptosis by activating p53-mediated signaling, leading to suppression of growth in resistant cancer cells [68].”
BackgroundTilekar, K. N., Upadhyay, N., Iancu, C. V., Pokrovsky, V. S., Choe, J., & Ramaa, C. S. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188457 · Cited by 95 · cited 2×
“esters [60], pyrazolo-pyrimidines [37], quinazolines [61], phenylalanine amides [62] and many more [35,58,63–67], EF24 [59], ketoximes [36], polyphenolic esters [60], pyrazolopyrimidines [37], quinazolines [61], phenylalanine amides [62], and many more [63–67], have emerged but need to be more deeply investigated.”
BackgroundLi, J., Zhou, S., Yu, J., Cai, W., Yang, Y., Kuang, X., Liu, H., He, Z., & Wang, Y. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.040 · Cited by 94
Li, L., Fath, M. A., Scarbrough, P. M., Watson, W. H., & Spitz, D. R. (2014) · Redox Biology · doi:10.1016/j.redox.2014.12.001 · Cited by 93
Fu, D., Li, J., Wei, J., Zhang, Z., Luo, Y., Tan, H., & Ren, C. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0219-0 · Cited by 92
The molecular basis of targeting PFKFB3 as a therapeutic strategy against cancer
Luo, L., Chen, Y., & Zhu, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.19513 · Cited by 91
Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2
Babu, M. S., Mahanta, S. K., Lakhter, A. J., Hato, T., Paul, S., & Naidu, S. R. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191419 · Cited by 90
The potential utility of PFKFB3 as a therapeutic target
Bartrons, R., Rodríguez-García, A., Simon-Molas, H., Castaño, E., Manzano, A., & Navarro-Sabaté, À. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1498082 · Cited by 90
Flavonoids Are Potential Inhibitors of Glucose Uptake in U937 Cells
Park, J. B. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0890 · Cited by 89 · cited 1×
“In addition, natural products such as trehalose (Figure 3K) [78], silibinin (Figure 3L) [79], curcumin (Figure 3M) [80], resveratrol (Figure 3N) [81], naringenin [82], quercetin [83], isoquercetin [84], kaempferol [85], xanthohumol [86], caffeine [87], bezielle [88], theophylline [89], (+)-Cryptocaryone [90], and mela…”
BackgroundQuercetin inhibits glucose transport by binding to an exofacial site on GLUT1
Hamilton, K. E., Rekman, J. F., Gunnink, L. K., Busscher, B. M., Scott, J. L., Tidball, A. M., Stehouwer, N. R., Johnecheck, G. N., Looyenga, B. D., & Louters, L. L. (2018) · Biochimie · doi:10.1016/j.biochi.2018.05.012 · Cited by 89
The Progress and Development of GLUT1 Inhibitors Targeting Cancer Energy Metabolism
Meng, Y., Xu, X. J., Luan, H., Li, L., Dai, W., Li, Z., & Bian, J. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0052 · Cited by 89 · cited 1×
“In addition, LDHA can also promote lactate production, thereby remodeling the TME and suppressing the immune system to promote immune escape [23,65].”
BackgroundZhou, Y., Zheng, X., Lu, J., Chen, W., Li, X., & Zhao, L. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000488273 · Cited by 88
Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment
Zhou, Y., Huang, Z., Su, J., Li, J., Zhao, S., Wu, L., Jiangling, Z., He, Y., Zhang, G., Tao, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32756 · Cited by 88
Self-citationNawaz, M. H., Ferreira, J. C., Nedyalkova, L., Zhu, H., Carrasco‐López, C., Kırmızıaltın, S., & Rabeh, W. M. (2018) · Bioscience Reports · doi:10.1042/bsr20171666 · Cited by 87
Wang, L., Yang, Q., Peng, S., & Liu, X. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s212465 · Cited by 87
A Nanounit Strategy Disrupts Energy Metabolism and Alleviates Immunosuppression for Cancer Therapy
Luo, Y., Li, Y., Huang, Z., Li, X., Wang, Y., Hou, J., & Zhou, S. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c02475 · Cited by 86
Self-citationBerruti, A., Bitossi, R., Gorzegno, G., Bottini, A., Alquati, P., Matteis, A. D., Nuzzo, F., Giardina, G., Danese, S., Lena, M. D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.012 · Cited by 84
Houddane, A., Bultot, L., Novellasdemunt, L., Johanns, M., Gueuning, M.-A., Vertommen, D., Coulie, P. G., Bartrons, R., Hue, L., & Rider, M. H. (2017) · Cellular Signalling · doi:10.1016/j.cellsig.2017.02.019 · Cited by 84
Li, W., Hao, J., Zhang, L., Cheng, Z., Deng, X., & Shu, G. (2017) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.7b02120 · Cited by 84
Seo, M., Kim, J.-D., Neau, D., Sehgal, I., & Lee, Y.-H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024179 · Cited by 82
Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation
Kraus, D., Reckenbeil, J., Veit, N., Kuerpig, S., Meisenheimer, M., Beier, I., Stark, H., Winter, J., & Probstmeier, R. (2018) · Cellular Oncology · doi:10.1007/s13402-018-0385-5 · Cited by 82 · cited 2×
“Therefore, STF-31 is non-toxic to normal tissues and can selectively kill cancer cells [43,44].”
BackgroundYang, Y., Cao, Y. Z., Chen, L., Liu, F., Qi, Z., Cheng, X., & Wang, Z. (2018) · Cancer Medicine · doi:10.1002/cam4.1691 · Cited by 82
Glucose transporter 1 regulates the proliferation and cisplatin sensitivity of esophageal cancer
Sawayama, H., Ogata, Y., Ishimoto, T., Mima, K., Hiyoshi, Y., Iwatsuki, M., Baba, Y., Miyamoto, Y., Yoshida, N., & Baba, H. (2019) · Cancer Science · doi:10.1111/cas.13995 · Cited by 82
Mohammad, G. H., Vassileva, V., Acedo, P., Olde Damink, S. W. M., Malago, M., Dhar, D. K., & Pereira, S. P. (2019) · Cancers · doi:10.3390/cancers11091372 · Cited by 82
Liposomes as Multifunctional Nano-Carriers for Medicinal Natural Products
Cheng, X., Yan, H., Pang, S., Ya, M., Qiu, F., Qin, P., Zeng, C., & Lu, Y. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.963004 · Cited by 81
Chaube, B., Malvi, P., Singh, S. V., Mohammad, N., Meena, A. S., & Bhat, M. K. (2015) · Oncotarget · doi:10.18632/oncotarget.6134 · Cited by 80
Cited by
Altered metabolism in cancer: insights into energy pathways and therapeutic targets
Tufail, M., Jiang, C.-H., & Li, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02119-3 · Cited by 534
“By inhibiting glucose transporters, specifically GLUT1, which is often overexpressed in various cancers, these inhibitors effectively starve cancer cells of their primary energy source [60, 216].”
BackgroundUnveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
“Further reports suggest the resistance dependence of cancer cells on glycolytic intermediate and glucose transporter are therapeutically significant nodes in both preclinical and clinical settings [292].”
BackgroundModulating Glycolysis to Improve Cancer Therapy
Chelakkot, C., Chelakkot, V. S., Shin, Y., & Song, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032606 · Cited by 374
“Additionally, several of the glycolysis inhibitors that have been developed for clinical use have been shown to have off-target effects, killing non-cancerous cells [327].”
BackgroundWang, Z., Zhang, X., Fang, C., Liu, X., Liao, Q., Wu, N., & Wang, J. (2024) · Immunology · doi:10.1111/imm.13793 · Cited by 204
“As a result, inhibiting glucose metabolism enzymes has shown great promise as a novel cancer treatment strategy [140 – 142].”
Lu, H., Tong, W., Jiang, M., Liu, H., Meng, C., Wang, K., & Mu, X. (2024) · ACS Nano · doi:10.1021/acsnano.4c04024 · Cited by 105
Metadata
- Authors
- Zhang, Y., Li, Q., Huang, Z., Li, B., Nice, E. C., Huang, C., Wei, L., & Zou, B.
- Affiliations
- Sichuan University (CN)
- Monash University (AU)
- Weifang Medical University (CN)
- Corresponding author
- Wei, Liuya
- Zou, Bingwen
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2022-09-21
- Volume
- 14
- Issue
- 19
- Pages
- 4568
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC9559313
- OpenAlex
- W4296991129
- Cited by
- 144
- References
- 322
- Citations by year
- 2026: 21 · 2025: 54 · 2024: 40 · 2023: 28 · 2022: 1
- FWCI
- 3.71
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Clinical Research Incubation Project, West China Hospital, Sichuan University (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
- Science and Technology Department of Sichuan Province (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
- Beijing Medical Award Foundation (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
- 1·3·5 project for disciplines of excellence (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
- National Natural Science Foundation of China (2021HXFH022, 22GJHZ0015, YXJL-2021-1009-0660, ZYGD22007, 82130082)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- glucose metabolism reprogramming, glucose metabolism enzymes, cancer metabolism, anticancer drug development, metabolic therapy, natural products, small molecule modulators, combination therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.